Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

NCT01802749 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

406

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Ovarian Cancer

Interventions

DRUG: Bevacizumab
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: pegylated liposomal doxorubicin
DRUG: Gemcitabine

Sponsor

National Cancer Institute, Naples

Collaborators

[object Object]